Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine... see more

NDAQ:PMN - Post Discussion

ProMIS Neurosciences Inc > Talking Down Good News
View:
Post by bball67 on Mar 02, 2022 2:01pm

Talking Down Good News

Reminds me of when we had double digit same store sales growth and the naysayor says but you were up against easy comparisons or the basketball player who just scored 30 and someone brings up a missed free throw. I thought your guys wanted a significant press release. 

Significant means significant. No AD vs AD, big difference. Indistinguishable difference with control group, that is significant. The details and readouts of thousands of pages of documentation are not appropriate for a biopharma press release. The Company believes that these results were significant. Bought another 45,000 shares yesterday and today with no worries. I am very confident about where this is going.
Comment by Speyeder999 on Mar 02, 2022 2:41pm
45000 shares is a significant amount of shares! (lol) Goodluck Bball, would have done the same if I had the budget! 
Comment by FarmerBetty on Mar 02, 2022 2:45pm
Old, recycled data how many in vivo tests do they have going back 5,6,7 years? That's why it won't move the stock. The same with PD, ALS, been running pre clinical mouse models for years, additional tests to verify as they reported a couple of years ago. Bottom line is they don't have any Pharma interest with any of their products and until they do their testing, extra testing ...more  
Comment by bball67 on Mar 02, 2022 3:21pm
Farmer John aka Mr Mole, talking down a stock, saying it is recyled news and that there is nothing here is an extremely negative interpretation. I had been questionning whether you were really bullish on this stock. Now I know your true orientation. You have incredible disdain for the Company. This is NOT the the in vivo test done 3-4 years ago. You can be of the opinion that it means nothing. I ...more  
Comment by Mole101 on Mar 02, 2022 3:47pm
Im not that Farmer .. neither pumping/ bashing ,  after 5 years invested here and not farther ahead on the development  than  2017 , forgive me if at times I question the companies motives , I've learned to sale any heights and buy the lows in the hope that one day , We can truly be rewarded .. keep  in mind   ( March 2021)   Debenture Terms The Debentures ...more  
Comment by FarmerBetty on Mar 02, 2022 3:56pm
No disdain just stating facts, they have been doing mouse testing for years on their programs. Where PMN 310 is today is not from today's anouncement  but builds on earlier mouse testing as announced in the marketherald today.
Comment by M101 on Mar 02, 2022 4:20pm
Yup, years, so if they want a different market result for a similar lab result then they need a change in promotional strategy.  How about a viral video featuring Algernon 2.0 solving back-yard squirrel mazes with live crows watching before and after treatment? How about asking Martin Tolar, or just moving Gene out of the PR loop? Something has to change to get a different result.
Comment by azzymaa on Mar 03, 2022 11:23am
M101, No idea they were doing this for years. But why put out a statement now? it's funny that the sp goes up to 0.15 cad and dips every singe time there is a pr. you would think after this pr that the sp would go way up or maybe we the investors are the practice mice. gene making half a mil is bs. 
Comment by DavidKingCanada on Mar 02, 2022 4:37pm
  It seems everyone here has multiple Usernames! Pathetic!  Kevin the Promoter is probably having a good chuckle! 
Comment by FarmerBetty on Mar 03, 2022 9:34am
Back to those options for Neil and Eugene granted 3,000 each expire in 10 years 2032, i read these as granted not converted to shares? Am i wrong? 
Comment by DavidKingCanada on Mar 03, 2022 10:43am
FarmerBetty aka Mole101 who cares what happens in 10 Years from now and even if PMN will still be there. Let's focus on the next 1-3 Years. If they get to the Nasdaq listing we will see a Increase in SP and then once again a giant Fall.  Still can't justify the CEO taking home $500,000.00 every Year! This is plain and simple Robbery! Any words from Mr Kevin the Promoter? 
Comment by azzymaa on Mar 03, 2022 11:40am
bball Ok so this pr is different from the rest of them as m101 was stating. that is good to know. 
Comment by M101 on Mar 02, 2022 3:36pm
If what the company believed was the standard then Aducanumab worked. "thousands of pages of documentation are not appropriate for a press release" ? Yes well, hard to argue with that when one paragraph or table would suffice.  
Comment by azzymaa on Mar 03, 2022 11:46am
bball wait a minute another 45000 shares? I thought promis was only 1 percent of your multimillion dollar portfolio? don't know if you are a troll or just plain old dumb. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities